Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine Treatment on Biomarkers of AD in Healthy Volunteers
NCT02288000Phase 1Terminated
- Sponsor
- CHU de Lille
- Start
- Sep 2016
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing Memantine with Placebo (2 arms). Primary endpoint: Pharmacog battery at 15 days. Started Sep 2016; status: terminated.
02
Drugs
memantine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02288000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02288000.